Shield Therapeutics plc (STX) — Cash Flow-to-Debt Ratio
Shield Therapeutics plc (STX) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2025, meaning its operating cash flow of GBX-4.49 Million could theoretically repay 0% of its total liabilities (GBX76.96 Million) in one year. Check how aggressively does Shield Therapeutics plc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Shield Therapeutics plc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Shield Therapeutics plc across 11 annual periods. Also explore Shield Therapeutics plc (STX) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Shield Therapeutics plc (2014–2024)
Year-by-year debt coverage analysis for Shield Therapeutics plc. For market capitalisation and broader financial context, see STX company net worth.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.15x | GBX-7.01 Million | GBX46.95 Million | ▲ +89.4% |
| 2023 | -1.40x | GBX-37.13 Million | GBX26.49 Million | ▼ -27.9% |
| 2022 | -1.10x | GBX-18.25 Million | GBX16.65 Million | ▲ +77.9% |
| 2021 | -4.95x | GBX-16.74 Million | GBX3.38 Million | ▼ -696.6% |
| 2020 | -0.62x | GBX-1.40 Million | GBX2.25 Million | ▲ +36.2% |
| 2019 | -0.97x | GBX-4.07 Million | GBX4.17 Million | ▼ -1515.0% |
| 2018 | -0.06x | GBX-178.00K | GBX2.95 Million | ▲ +98.6% |
| 2017 | -4.29x | GBX-16.15 Million | GBX3.76 Million | ▼ -66.9% |
| 2016 | -2.57x | GBX-10.26 Million | GBX3.99 Million | ▼ -1222.0% |
| 2015 | -0.19x | GBX-4.18 Million | GBX21.50 Million | ▼ -12.3% |
| 2014 | -0.17x | GBX-3.34 Million | GBX19.29 Million | — |